An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies.
J Immunother
; 39(8): 298-305, 2016 10.
Article
em En
| MEDLINE
| ID: mdl-27488724
ABSTRACT
Immunomodulatory monoclonal antibodies (mAbs) have efficacy in patients with advanced cancer and are the focus of intensive research. However, cures are infrequent and responses vary among tumor types and among subjects with the same tumor. An in vitro test would be valuable to determine the most effective mAb combination for a given case and to evaluate novel agents. Toward this goal, we investigated the ability of various mAb combinations to generate a tumor-destructive immune response in vitro in the presence of lymphoid cells from mice with established TC1 lung carcinoma, B16 melanoma, or SW1 melanoma. The data strongly correlate (r=0.9, 0.89, and 0.91, respectively) with the therapeutic efficacy of the respective mAb combinations. Both in vivo and in vitro, tumor destruction was associated with a shift from a Th2 to a Th1 response and included a dramatic increase of long-term memory cells. A combination of mAbs to CD137/PD-1/CTLA4/CD19 was most efficacious.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Melanoma Experimental
/
Células Th2
/
Neoplasias Pulmonares
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article